Loading
A phase 3 trial of Revumenib in acute myeloid leukaemia, run by Syndax Pharmaceuticals, now recruiting.
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation is a phase 3 interventional study registered as NCT07211958 by Syndax Pharmaceuticals, with 468 participants planned, started 2025-11-25 and due to reach its primary completion in 2029-06. Interventions recorded: Revumenib, Placebo and Intensive Chemotherapy Regimen.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/